Federal Trade Commission Sues Big Pharma Middlemen for Inflating Insulin Prices
The FTC is legally challenging major pharmacy benefit managers for inflating insulin prices and blocking patient access to cheaper drugs.
Independent pharmacies say they're being squeezed by shadowy middlemen tied to big health chains
Independent pharmacists face existential threats from pharmacy benefit managers that steer patients away and impose high fees, jeopardizing community healthcare.
Drug middlemen illegally drive up the cost of insulin, FTC says
Federal regulators accuse major pharmacy benefit managers of driving up insulin costs and limiting access to cheaper versions, impacting millions of diabetes patients.
Pharmacy Benefit Managers Aren't Always Good for Pharmacies
Pharmacy deserts are emerging in the U.S. as independent pharmacies close due to the practices of pharmacy benefit managers.
Letters: Restrain PBMs
Congress must act to regulate pharmacy benefit managers (PBMs) to protect patient access to medications and support independent pharmacies.
FTC says prescription middlemen are squeezing Main Street pharmacies
Prescription drug middlemen, known as PBMs, inflate drug prices, overcharge cancer patients, and squeeze independent pharmacies, impacting accessibility, cost, and care for Americans.
Federal Trade Commission Sues Big Pharma Middlemen for Inflating Insulin Prices
The FTC is legally challenging major pharmacy benefit managers for inflating insulin prices and blocking patient access to cheaper drugs.
Independent pharmacies say they're being squeezed by shadowy middlemen tied to big health chains
Independent pharmacists face existential threats from pharmacy benefit managers that steer patients away and impose high fees, jeopardizing community healthcare.
Drug middlemen illegally drive up the cost of insulin, FTC says
Federal regulators accuse major pharmacy benefit managers of driving up insulin costs and limiting access to cheaper versions, impacting millions of diabetes patients.
Pharmacy Benefit Managers Aren't Always Good for Pharmacies
Pharmacy deserts are emerging in the U.S. as independent pharmacies close due to the practices of pharmacy benefit managers.
Letters: Restrain PBMs
Congress must act to regulate pharmacy benefit managers (PBMs) to protect patient access to medications and support independent pharmacies.
FTC says prescription middlemen are squeezing Main Street pharmacies
Prescription drug middlemen, known as PBMs, inflate drug prices, overcharge cancer patients, and squeeze independent pharmacies, impacting accessibility, cost, and care for Americans.
FTC sues insulin middlemen, saying they pocket billions while patients face high costs
The FTC is targeting pharmacy benefit managers to address high insulin costs, which have shot up by 600% over two decades, impacting diabetic patients.
FTC goes after drug middlemen for allegedly jacking up insulin prices
The FTC is suing three PBMs for allegedly inflating insulin prices, impacting many Americans reliant on the drug.
Video: Besides, Pharma and PBMs, Who Drives Up Drug Costs? - MedCity News
Bipartisan scrutiny highlights the complexities of prescription drug pricing, implicating pharmacy benefit managers, Big Pharma, distributors, and hospitals in driving costs up.
The Opaque Industry Secretly Inflating Prices for Prescription Drugs
Pharmacy benefit managers often go unnoticed but significantly contribute to the rising costs of prescription drugs for millions of Americans.
Hospitals and PBMs seem to have dodged big federal reforms - for now
Hospitals and pharmacy benefit managers avoided major federal reforms in the recent congressional spending deal.
The lack of big policy changes could potentially lead to higher health costs for patients.
FTC sues insulin middlemen, saying they pocket billions while patients face high costs
The FTC is targeting pharmacy benefit managers to address high insulin costs, which have shot up by 600% over two decades, impacting diabetic patients.
FTC goes after drug middlemen for allegedly jacking up insulin prices
The FTC is suing three PBMs for allegedly inflating insulin prices, impacting many Americans reliant on the drug.
Video: Besides, Pharma and PBMs, Who Drives Up Drug Costs? - MedCity News
Bipartisan scrutiny highlights the complexities of prescription drug pricing, implicating pharmacy benefit managers, Big Pharma, distributors, and hospitals in driving costs up.
The Opaque Industry Secretly Inflating Prices for Prescription Drugs
Pharmacy benefit managers often go unnoticed but significantly contribute to the rising costs of prescription drugs for millions of Americans.
Hospitals and PBMs seem to have dodged big federal reforms - for now
Hospitals and pharmacy benefit managers avoided major federal reforms in the recent congressional spending deal.
The lack of big policy changes could potentially lead to higher health costs for patients.
Wells Fargo employees sue for overpaying for prescription drugs through the company's health insurance plan
Wells Fargo accused of mismanaging employee health plan, overcharging for drugs.
These Middlemen Say They Keep Drug Prices Low. California Lawmakers Don't Buy It | KQED
Prescription drug costs in California surged 39% in five years, prompting calls for regulatory action to protect patients.
CA Lawmakers Skeptical that Pharma Managers Will Look Out for Consumers
California is seeking to regulate pharmacy benefit managers to control rising prescription drug costs, driven by intermediaries' profit-driven practices.
Wells Fargo employees sue for overpaying for prescription drugs through the company's health insurance plan
Wells Fargo accused of mismanaging employee health plan, overcharging for drugs.
These Middlemen Say They Keep Drug Prices Low. California Lawmakers Don't Buy It | KQED
Prescription drug costs in California surged 39% in five years, prompting calls for regulatory action to protect patients.
CA Lawmakers Skeptical that Pharma Managers Will Look Out for Consumers
California is seeking to regulate pharmacy benefit managers to control rising prescription drug costs, driven by intermediaries' profit-driven practices.